GlassScriptPhysician profile
Howard Likier
NPI 1679652820
$2,951.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $697 · 2021: $1,346 · 2022: $628.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,075.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.55 | 2019-2022 | |
| Janssen Biotech, INC. | $282.82 | 2019-2022 | |
| Gilead Sciences, INC. | $235.44 | 2019-2022 | |
| Qol Medical, LLC | $188.97 | 2021-2022 | |
| Abbvie INC. | $173.71 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $167.46 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $82.87 | 2019-2021 | |
| Celgene Corporation | $75.52 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $73.67 | 2021 | |
| Merck Sharp & Dohme LLC | $56.72 | 2021-2022 | |
| Vivus LLC | $38.94 | 2021 | |
| Redhill Biopharma INC. | $37.01 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.94 | 2020-2022 | |
| Ardelyx, INC. | $18.41 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Likier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.